KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Gross Margin: 2018-2025

Historic Gross Margin for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to 77.48%.

  • Castle Biosciences' Gross Margin fell 433.00% to 77.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.94%, marking a year-over-year decrease of 196.00%. This contributed to the annual value of 81.87% for FY2024, which is 234.00% up from last year.
  • Castle Biosciences' Gross Margin amounted to 77.48% in Q3 2025, which was down 2.61% from 79.55% recorded in Q2 2025.
  • Castle Biosciences' Gross Margin's 5-year high stood at 86.73% during Q1 2021, with a 5-year trough of 75.17% in Q4 2022.
  • Over the past 3 years, Castle Biosciences' median Gross Margin value was 81.21% (recorded in 2023), while the average stood at 80.21%.
  • In the last 5 years, Castle Biosciences' Gross Margin crashed by 886bps in 2022 and then spiked by 604bps in 2023.
  • Over the past 5 years, Castle Biosciences' Gross Margin (Quarterly) stood at 81.64% in 2021, then slumped by 647bps to 75.17% in 2022, then spiked by 604bps to 81.21% in 2023, then grew by 4bps to 81.25% in 2024, then tumbled by 433bps to 77.48% in 2025.
  • Its Gross Margin stands at 77.48% for Q3 2025, versus 79.55% for Q2 2025 and 81.38% for Q1 2025.